By Doug Macron

Arrowhead Research's CEO last week struck an optimistic note about the company's drug-development efforts by stating that its Calando Pharmaceuticals subsidiary remains on track to complete a phase I study of its siRNA-based cancer drug, and partner the program before the end of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcrips, and more.

After seeing Rich's image of the DNA double helix structure in 1973, James Watson called Rich and told him that it was the first time in 20 years he'd had a good night's sleep.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.